Suplemento de cogumelo de botão branco para a redução do PSA em pacientes com bioquimicamente rec ou terapia ingênua Fav risco próstata CA
Um estudo randomizado de fase 2 do suplemento de cogumelo branco em pacientes com câncer de próstata bioquimicamente recorrente após terapia local e em pacientes sem tratamento com risco favorável de câncer de próstata submetidos a vigilância ativa
This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not undergone any therapy (therapy naive). PSA is a blood marker of prostate growth. White button mushroom supplement may affect PSA level, various parameters of immune system and levels of hormones that may have a role in prostate cancer growth.
Visão geral do estudo
Status
Status
Condições
Condições
- Adenocarcinoma de próstata
- Carcinoma de próstata recorrente
- Câncer de Próstata Estágio I AJCC v8
- Câncer de Próstata Estágio IIIA AJCC v8
- Câncer de Próstata Estágio IIC AJCC v8
- Câncer de Próstata Estágio IIIC AJCC v8
- Falha de PSA
- Progressão do PSA
- Câncer de Próstata Estágio IIA AJCC v8
- Câncer de Próstata Estágio IIB AJCC v8
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. To assess the proportion of patients with any prostate specific antigen (PSA) reduction at 12 weeks (~3 months) in observation + white button mushroom (WBM) supplement arm and observation only arm (control arm). (Cohort 1) II. To assess relative change in PSA at 48 weeks (~12 months) from baseline with or without WBM treatment. (Cohort 2)
SECONDARY OBJECTIVES:
I. To evaluate, adverse events, PSA-response rate and time to PSA progression. (Cohort 1) II. To evaluate adverse events, time to initiation of additional therapy and progression. (Cohort 2)
EXPLORATORY OBJECTIVES:
I. To characterize the immunomodulatory effects of WBM supplement in serial blood samples. (Cohort 1) II. To assess the effect of therapy with WBM on sexual function. (Cohort 1) III. To assess the effect of WBM on Gleason grade in prostate cancer subjects on active surveillance. (Cohort 2) IV. To characterize the immunomodulatory effects of WBM supplement in serial blood samples and in tumor tissue. (Cohort 2) V. To characterize changes in cancer signaling pathways in tumor tissue after intake of WBM supplement. (Cohort 2) VI. To assess the effect of WBM supplement on sexual function. (Cohort 2)
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Biochemically recurrent prostate cancer patients are randomized to 1 of 2 arms.
ARM IA: Patients receive white button mushroom extract orally (PO) twice daily (BID) on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.
ARM IB: Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.
COHORT II: Therapy naive favorable risk prostate cancer patients are randomized to 1 of 2 arms.
ARM IIA: Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.
ARM IIB: Patients undergo active surveillance for 48 weeks.
After completion of study treatment, patients are followed up at 30 days.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope Medical Center
-
Glendora, California, Estados Unidos, 91741
- City of Hope at Glendora
-
Irvine, California, Estados Unidos, 92618
- City of Hope at Irvine Lennar
-
Rancho Cucamonga, California, Estados Unidos, 91730
- City of Hope Rancho Cucamonga
-
Santa Monica, California, Estados Unidos, 90404
- John Wayne Cancer Institute
-
South Pasadena, California, Estados Unidos, 91030
- City of Hope South Pasadena
-
West Covina, California, Estados Unidos, 91790
- City of Hope West Covina
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Documented informed consent of the participant and/or legally authorized representative
-
For therapy naive favorable risk prostate cancer (cohort 2 only): agreement to undergo baseline and 48 week prostate biopsy
-
Willing to forego non-study supplements containing mushroom for the duration of the study
-
Eastern Cooperative Oncology Group (ECOG) =< 2
-
Histologically or cytologically confirmed history of adenocarcinoma of the prostate
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: PSA failure defined as:
- PSA of >= 0.2 ng/mL that has increased above nadir following prostatectomy, OR
- PSA increase of 2.0 ng/mL above post-therapy nadir if other primary local therapy was used instead of prostatectomy
- NOTE: PSA value must be increasing based on 2 consecutive measurements taken at least 2 weeks apart
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Testosterone levels > 50 ng/dL
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Received any number of primary local therapies, defined as:
- Radical prostatectomy
- External beam radiation therapy
- Radioactive seed implantation
- Cryotherapy
- High-intensity focused ultrasound (HIFU)
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: May have received up to 24 months of neoadjuvant/adjuvant androgen deprivation therapy in conjunction with primary local therapy. Androgen deprivation therapy must have been completed > 6 months from day (D)1 of the study
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant cytotoxic chemotherapy must have been completed > 6 months from day (D)1 of the study
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: No clinical or radiographic evidence of metastatic disease within 2 months prior to day 1 of protocol therapy. If metastatic disease is detected by positron emission tomography (PET) imaging only patients are eligible as long as no metastatic disease is noted on computed tomography (CT) scan (or magnetic resonance imaging [MRI]) and bone scan
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adenocarcinoma of the prostate diagnosed =< 12 months of protocol screening and has elected active surveillance as preferred management plan OR already on active surveillance
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Clinical stage T1c-T2a as defined below:
- T1c: Tumor identified by needle biopsy found in one or both sides, but not palpable
- T2a: Tumor involves one-half of one side or less
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Gleason score =< 6 (grade group 1) or Gleason 3+4 (grade group 2)
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adequate biopsy of at least 10 biopsy cores
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: No prior therapy for prostate cancer defined as:
- Local therapy including surgery , radiation or focal therapy (cryoablation, HIFU, light)
- Systemic therapy (hormonal, immunotherapy, targeted, chemotherapy). Subjects who have used 5-alpha reductase inhibitor (e.g. finasteride or dutasteride) > 6 months prior to D1 of protocol therapy will be allowed
-
Platelets > 100,000 /mm^3 (within 28 days prior to day 1 of protocol therapy)
-
Hemoglobin > 8 g/dL (within 28 days prior to day 1 of protocol therapy)
-
Aspartate aminotransferase, alanine aminotransferase, < 3 x upper limit of normal (ULN) (within 28 days prior to day 1 of protocol therapy)
-
Total bilirubin < 2 x ULN (within 28 days prior to day 1 of protocol therapy)
-
Creatinine < 2 x ULN (within 28 days prior to day 1 of protocol therapy)
Exclusion Criteria:
-
Other concomitant investigational anti-cancer therapy/ vaccines/biologics, corticosteroids with > 10 mg of prednisone equivalent dose
-
Therapy with mushroom supplements within last 3 months of randomization
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant androgen derivation therapy lasting > 24 months or within 6 months prior to day 1 of protocol therapy
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant chemotherapy within 6 months prior to day 1 of protocol therapy
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Prior therapy for recurrent prostate cancer (unless given as a component of attempted curative salvage treatment including salvage radiation therapy, and completed > 6 months before day 1 of protocol therapy):
- Chemotherapy
- Androgen deprivation therapy
- Immunotherapy
- Targeted therapy
-
Known history of allergic reaction to mushrooms
-
Clinically significant uncontrolled illness
-
Active infection requiring treatment
-
Uncontrolled congestive heart failure, cardiac arrhythmia
-
History of other primary non-skin malignancy within previous 2 years unless treated with curative intent and in remission
-
Any other condition that would, in the Investigator?s judgment, contraindicate the patient?s participation in the clinical study due to safety concerns with clinical study procedures
-
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Arm IA (white mushroom extract)
Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity. |
Ancillary studies Given PO
Outros nomes:
|
|
Comparador Ativo: Arm IB (clinical observation)
Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA. |
Ancillary studies Undergo clinical observation
Outros nomes:
|
|
Experimental: Arm IIA (white mushroom extract)
Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity. |
Ancillary studies Given PO
Outros nomes:
|
|
Comparador Ativo: Arm IIB (active surveillance)
Patients undergo active surveillance for 48 weeks. |
Ancillary studies Undergo active surveillance
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Prostate-specific antigen (PSA) (ng/mL) levels (Cohort 1)
Prazo: At 12 weeks
|
For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
At 12 weeks
|
|
Relative change in PSA (Cohort 2)
Prazo: Baseline up to 48 weeks
|
The relative difference in PSA will be measured as log (48 week PSA/baseline PSA). Undetectable PSA at 48 weeks will be coded as the low end of the lab measurement range for PSA. This measure of relative difference will be compared between the white button supplement (WBM) + active surveillance and active surveillance only patients. For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
Baseline up to 48 weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of adverse events
Prazo: Up to 48 weeks
|
Will be defined per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Grade 2 serious adverse events and all grade 3-5 adverse events will be reported in the e-case report forms. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, attribution, time of onset, probable association with the study treatment and reversibility or outcome. |
Up to 48 weeks
|
|
Proportion of patients with PSA response (Cohort 1)
Prazo: Up to 48 weeks
|
Will be defined as the sum of complete (PSA-normalization) and partial responders (PSA-partial response) vs non-responders. For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
Up to 48 weeks
|
|
Time to PSA progression (Cohort 1)
Prazo: Time from randomization to PSA progression, assessed up to 48 weeks
|
For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
Time from randomization to PSA progression, assessed up to 48 weeks
|
|
Time to initiation of additional therapy (Cohort 2)
Prazo: Baseline up to 48 weeks
|
For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
Baseline up to 48 weeks
|
|
Time to progression (Cohort 2)
Prazo: From randomization to progression, assessed up to 48 weeks
|
Will be defined as any Gleason grade 4 or 5 upon repeat biopsy or conversion from 3+4 to 4+3 or higher, prostate cancer is found in a greater number of prostate biopsy cores, prostate cancer occupies a greater extent of the prostate biopsy cores, PSA > 100 ng/mL. For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
From randomization to progression, assessed up to 48 weeks
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in temporal levels of circulating myeloid-derived suppressor cells (MDSCs)
Prazo: Baseline to 48 weeks
|
Will be studies within the peripheral blood mononuclear cell (PBMC) compartment. Will evaluate the relative change in prostate cancer-associated MDSCs after 12 weeks of WBM supplement intake in borderline resectable pancreatic cancer patients versus in those on observation using a two group t-test. Results for cohort 1 will be confirmed by analyzing prostate cancer-associated MDSCs in cohort 2 as well (change from baseline to 48 weeks). |
Baseline to 48 weeks
|
|
Change in temporal levels of pro-/anti-inflammatory mediators
Prazo: Baseline up to 48 weeks
|
Will include cytokines/growth factors/chemokines, including IL-15 in plasma. Will evaluate the baseline correlatives and the relative role of treatment in a multivariate exploratory analysis. |
Baseline up to 48 weeks
|
|
Sexual function
Prazo: Up to 48 weeks
|
Will be evaluated by the sexual function questionnaire, including the Sexual Health Inventory for Men score. The Sexual Health Inventory for Men (SHIM) Questionnaire scoring system will be used. |
Up to 48 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Clayton S Lau, City of Hope Medical Center
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Neoplasias Genitais Masculinas
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Genitais, Masculino
- Doenças prostáticas
- Doenças Urogenitais Masculinas
- Neoplasias prostáticas
- Administração de Serviços de Saúde
- Técnicas de investigação
- Métodos
- Qualidade de assistência médica
- Avaliação de resultados, assistência médica
- Avaliação de resultados e processos, assistência médica
- Observação
- Esperando vigilante
Outros números de identificação do estudo
Outros números de identificação do estudo
- 19296
- P30CA033572 (Concessão/Contrato do NIH dos EUA)
- 19296 (Outro identificador: City of Hope Medical Center)
- NCI-2019-05587 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .